Mumbai-based CDMO ‘Influx Healthtech Limited’ Files DRHP with NSE Emerge
Influx Healthtech Limited (‘IHL’ or ‘The Company’), a leading Contract Development and Manufacturing Organisation specializing in nutraceuticals, cosmetics, veterinary feed, ayurvedic and homecare products, announced the filing of its Draft Red Herring Prospectus (DRHP) with NSE Emerge
image for illustrative purpose
Mumbai, Sep 10: Influx Healthtech Limited (‘IHL’ or ‘The Company’), a leading Contract Development and Manufacturing Organisation specializing in nutraceuticals, cosmetics, veterinary feed, ayurvedic and homecare products, announced the filing of its Draft Red Herring Prospectus (DRHP) with NSE Emerge. The Mumbai-based company’s IPO comprises a fresh issuance of 46,32,000 Equity Shares and an Offer for Sale of up to 13,68,000 Equity Shares, each with a face value of Rs. 10, through the book-building route. The Offer for Sale is made by the selling shareholder, Munir Abdul Ganee Chandniwala.
Corporate Capital Ventures is the sole Book Running Lead Manager to the offer, and Maashitla Securities Private Limited is the Registrar. Corporate Capital Ventures has completed a string of successful SME IPOs in recent months, including Nephro Care India Limited, Shivalic Power Control, GP Eco Solutions, Trust Fintech, Creative Graphics, Alpex Solar, Rockingdeals, Accent Microcell, Oriana Power, Droneacharya and Crayons Advertising, among others.
Influx Healthtech is a Contract Development and Manufacturing Organization (CDMO) specializing in the manufacturing of a diverse range of products across several segments, including Dietary/Nutraceuticals Supplements, Cosmetics, Ayurvedic / Herbal, Veterinary Feed Supplements, and Homecare segment. Its product portfolio includes Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms such as tablets, capsules, liquid orals, and powders. The company operates three state-of-the-art manufacturing facilities located at Palghar, Maharashtra, which are spread over land of 6,500 Sq Ft, 13,000 Sq Ft, and 14,000 Sq Ft.
According to DRHP, the company intends to utilise Rs. 21.61 crore of the total proceeds from the IPO to fund capital expenditure for setting up a new manufacturing facility for the Nutraceutical Division; Rs. 8.76 crore to fund capital expenditure for setting up a new manufacturing facility for the Veterinary Food Division and Rs. 2.66 crore to purchase machinery for Homecare and Cosmetic Division. It plans to use the remaining capital for general corporate expenses.
IHL serves multiple pharma and life sciences companies, including Bling Brands Private Limited, Pursuit of Wellness Private Limited, Aarkios Health Private Limited, HSHS Nutraceuticals Limited, Novus Life Science Private Limited, Bruder Life Science, Fredun Pharmaceuticals Limited and Bigflex Lifescience Private Limited. Influx Healthtech is WHO-GMP compliant, adhering to the stringent guidelines set by the World Health Organization. Its commitment to quality is further demonstrated by ISO 22000:2018 and ISO 14001:2015 certifications obtained from a Euro-UK certification body. The company also has FDA approval for products from the Food & Drugs Administration and Cosmetics Division as well.
Founded in 2020 by a visionary entrepreneur, Mr. Munir Abdul Ganee Chandniwala, Influx Healthtech has grown steadily under his leadership. With over 20 years of experience in the nutraceutical, cosmetics, ayurvedic, and homecare industries, Mr Chandniwala has been a successful entrepreneur in the fields of third-party manufacturing, contract development, and manufacturing. He holds a Doctor of Philosophy program from Bharatiya Shiksha Parishad, Uttar Pradesh and a diploma in Nutrition from Fab Academe, a division of Fabulous Body Inc., California, United States.
Influx Health-tech Limited registered Rs. 99.96 crore in revenue from operations with a profit (PAT) of Rs. 11.22 crore in the fiscal year 2023-24, compared to Rs. 76.05 crore in revenue from operations and a profit (PAT) of Rs. 7.19 crore in FY2022-23.
